ZYUS Life Sciences Corporation
ZLSCF
$0.5323
$0.133833.58%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.58% | -6.15% | 26.23% | 22.22% | 50.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.58% | -6.15% | 26.23% | 22.22% | 50.44% |
| Cost of Revenue | -6.58% | -9.40% | -43.95% | -39.14% | 60.57% |
| Gross Profit | 6.62% | -2.79% | 47.16% | 365.18% | 42.68% |
| SG&A Expenses | -25.66% | -7.24% | -55.80% | -27.15% | -20.81% |
| Depreciation & Amortization | -8.04% | -9.57% | -5.54% | -6.71% | 18.57% |
| Other Operating Expenses | -65.92% | 51.04% | 123.50% | -17.76% | -4.50% |
| Total Operating Expenses | -15.28% | 1.09% | -42.80% | -7.76% | -8.40% |
| Operating Income | 15.68% | -1.34% | 43.70% | 8.51% | 9.29% |
| Income Before Tax | 9.39% | -10.85% | 23.68% | 8.17% | 48.77% |
| Income Tax Expenses | -- | -- | 65.81% | 20.38% | 20.51% |
| Earnings from Continuing Operations | 9.07% | -11.42% | 13.72% | 8.11% | 48.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.07% | -11.42% | 13.72% | 8.11% | 48.83% |
| EBIT | 15.68% | -1.34% | 43.70% | 8.51% | 9.29% |
| EBITDA | 17.10% | -4.54% | 45.05% | 8.94% | 13.08% |
| EPS Basic | 14.72% | -6.30% | 18.72% | 11.16% | 66.98% |
| Normalized Basic EPS | 15.11% | -5.45% | 54.73% | 11.03% | 58.09% |
| EPS Diluted | 15.23% | 0.00% | 19.19% | 11.16% | 65.91% |
| Normalized Diluted EPS | 15.11% | -5.45% | 54.73% | 11.03% | 58.09% |
| Average Basic Shares Outstanding | 6.73% | 4.95% | 6.19% | 3.38% | 54.88% |
| Average Diluted Shares Outstanding | 6.73% | 4.95% | 6.19% | 3.38% | 54.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |